MET Inhibitor Immunotherapy for Aggressive Lung Cancer
Novel Combination Therapy Shows Promise in Combating Aggressive Small Cell Lung Cancer
Table of Contents
Small cell lung cancer (SCLC) is a particularly aggressive form of lung cancer, known for its rapid growth and tendency to develop resistance to treatment and metastasize. While chemotherapy and immunotherapy have become standard treatments, thier effectiveness is often limited by the emergence of resistance. Though, groundbreaking research from the Hospital del Mar in Barcelona offers a new avenue for improving outcomes in SCLC patients.
Overcoming Resistance with a MET Inhibitor
Researchers have discovered that adding a MET inhibitor to existing chemotherapy and immunotherapy regimens can substantially enhance treatment efficacy in preclinical models. This innovative approach addresses a key challenge in SCLC treatment: the tumor microenvironment’s ability to shield cancer cells from immune attack and drug penetration.
“We have seen that when immunotherapy and chemotherapy are combined with a MET inhibitor, this inhibitor is able to make immunotherapy work better, increasing survival and tumor response in mouse models,” explains Dr. Edurne Arriola, lead author of the study, Chief of the Lung Cancer section in the Medical Oncology Service of the Hospital del Mar, and a researcher at the Molecular Therapy Research Group and CIBERONC. this work represents the culmination of over a decade of dedicated research.
Enhanced efficacy in Murine Models
The study involved analyzing various therapeutic combinations in murine models. These included a control group receiving no treatment, a group receiving only chemotherapy, a group receiving chemotherapy plus immunotherapy (using the anti-PD-L1 monoclonal antibody), and a final group receiving the triple combination of chemotherapy, immunotherapy, and a MET inhibitor.
The most promising results – demonstrating both slowed tumor progression and improved survival rates – were observed in the group treated with the triple combination. Remarkably, six out of nine tumors in this group exhibited a complete response to the treatment.
Dr. Arriola emphasizes that the combination therapy not only slowed tumor growth but completely inhibited it in some cases. “When we analyzed survival and tumor progression, we saw that the survival of the mice treated with the inhibitor was superior,” she states. This prolonged response is attributed to the MET inhibitor’s ability to remodel the tumor microenvironment, which typically fosters resistance to treatment.
“When MET is inhibited, that microenvironment changes, which facilitates the action of T-system cells activated by immunotherapy,” Dr.Arriola adds. Essentially, the inhibitor doesn’t directly target the tumor cells but instead strengthens the effectiveness of standard treatments by making the tumor more vulnerable to the immune system.
Identifying Patients Most Likely to Benefit
The researchers further validated their findings by analyzing human tumor samples. They discovered that tumors with overexpression of the MET gene exhibit a more resistant microenvironment, leading to a poorer prognosis and reduced responsiveness to both chemotherapy and immunotherapy. This is a crucial finding, as approximately half of patients with SCLC demonstrate high MET expression levels. Identifying these patients through biomarker testing could allow for a more personalized and effective treatment approach.
Clinical Trial on the Horizon
Building on these encouraging preclinical results, the research team is preparing to launch a clinical trial in patients with small cell lung cancer. The trial will investigate whether adding the MET inhibitor during the maintenance phase – following initial treatment with chemotherapy and immunotherapy – can effectively halt tumor progression and improve long-term outcomes.
This pioneering research represents a meaningful step forward in the fight against one of the most lethal forms of lung cancer, offering hope for improved treatment strategies and ultimately, better survival rates for patients battling this devastating disease. The potential to refine treatment based on MET gene expression promises a future of more targeted and effective cancer care.